Product Description
APN01 is ideally suited to prevent the infection with SARS-CoV-2, reduce injury to multiple organs and mitigate the deleterious consequences of established viral infection.
Mechanisms of Action: ACE Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Apeiron Biologics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: COVID-19
Phase 1: Kidney Diseases|Lung Cancer|Vascular Cancer|Kidney Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| APN01-1-01 | P1 |
Completed |
Vascular Cancer|Kidney Cancer|Lung Cancer|Kidney Diseases |
2009-11-01 |
2019-03-18 |
Treatments |
|
| APN01-COVID-19 | P2 |
Completed |
COVID-19 |
2020-12-26 |
48% |
2021-08-04 |
Primary Endpoints |
| APN01-01-COVID19 | P2 |
Completed |
COVID-19 |
2020-12-26 |
2022-03-13 |
Treatments |